In vitro sensitivity of hematopoietic progenitors to Tiazofurin in refractory acute myeloid leukemia and in the blast crisis of chronic myeloid leukemia

Cancer Letters

Volumn 195, Issue 2, 2003, Pages 153-159

  Colovic, M ^a   Sefer, D ^a   Bogdanovic, A ^a   Suvajdzic N ^a   Jankovic, G ^a   Atkinson, H D E ^b   Milenkovic, P ^c  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c Institute for Medical Research   (Serbia)

Author keywords

Acute myeloid leukemia; Blast crisis; Chronic myeloid leukemia; Tiazofurin

Indexed keywords

METHYLCELLULOSE; TIAZOFURIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BLAST CELL CRISIS; BLOOD CELL; CELL COUNT; CELL CULTURE; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SAMPLE;

EID: 0038060245     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00152-6     Document Type: Article

References (21)

1. Weber G., Prajda N., Abonyi M., Look K.Y., Tricot G. Tiazofurin: molecular and clinical action. Anticancer Res. 16:1996;3313-3322.
2. Tricot G., Weber G. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity. Anticancer Res. 16:1996;3341-3348.
3. Sokoloski J.A., Sartorelli A.C. Effects of the inhibition of the IMP dehydrogenase, tiazofurin and mycophenolic acid on glycoprotein metabolism. Mol Pharmacol. 28:1985;567-573.
4. Yamada Y., Natsumeda Y., Yamaji Y., et al. IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin. Leuk Res. 13:(2):1989;179-184.
5. Weber G., Yamaji Y., Olah E., et al. Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin. Adv Enzyme Regul. 28:1989;335-356.
6. Wright D.G., Boosalis M.S., Waraska K., Oshry L.J., Weintraub L.S., Vosburgh E. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Anticancer Res. 16:1996;3349-3354.
7. Bennett J.M., Catovsky D., Daniel M.T.H., et al. Proposed revised criteria for the classification of the acute leukemia's French-American-British (FAB) Cooperative Group. Ann Into Med. 103:1985;620-625.
8. Aright H., McLaren P., et al. Chronic myelogenous leukemia. Hoffman R., Benz E.J., Shadily S.J., et al. Hematology, Basic principles and practice. 2000;1155-1169 Churchill, Livingston.
9. Burnett A., Goldstone A.H., Stevens R.M.F., et al. Randomized comparison of addition of autologous BM transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial. Lancet. 351:1998;700-708.
10. Preisler H.D., Larson R.A., Raza A., et al. The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukemia: response to treatment and treatment failure. Br J Haematol. 79:1991;390-397.
11. Minden M.D., Buick R.N., McCulloch E.A. Separation of blast cell and T-lymphocyte progenitors in the blood and patients with acute myeloblastic leukemia. Blood. 54:1979;186-195.
12. Marie J.P., Zittoun R., Thevenin D., Mathieu M., Vigne F. In vitro vulture of clonogenic leukemic cells in acute myeloid leukemia: growth pattern and drug sensitivity. Br J Haematol. 55:1983;427-437.
13. Tovari J., Bocsi J., Ladanyi A., Lapis K., Timar J. The antitumor effect of tiazofurin (TR) consists of anti-proliferative and anti-invasive elements. Anticancer Res. 16:1996;3307-3312.
14. Tricot G.J., Jarayam H.N., Nichols C.R., et al. Hematologic and biochemical action of tiazofurin (NSC 286 193) in a case of refractory acute myeloid leukemia. Cancer Res. 47:1987;4988-4991.
15. Weber G., Nagai M., Natsumeda Y., et al. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient. Cancer Commun. 3:(3):1991;61-66.
16. Stasi R., DelPoeta G., Masi M. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogene. 67:1993;28-34.
17. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma. 11(Suppl 1):1993;11-15.
18. Tricot G., Jarayam H.N., Weber G., Hoffman R. Tiazofurin: biological effects and uses. Int J Cell Cloning. 8:1990;161-170.
19. Jayaram H.N., Lapis E., Tricot G., et al. Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. Int J Cancer. 851:(2):1992;182-188.
20. Weber G. IMP dehydrogenase and DTP as targets in human leukemia treatment. Advan Expptl Med Biol. 309b:1991;287-292.
21. Grifantini M., Tiazofurine I.C.N. Pharmaceuticals. Curr Opin Investig Drugs. (2):2000;257-262.